Kling Biotherapeutics

Kling Biotherapeutics leverages a clinically validated B cell immortalization technology to discover novel targets and antibodies from elite patient responders. Its dual-platform approach, Kling-Select and Kling-Evolve, has generated a pipeline including a first-in-class CD9 antibody (KBA1412) currently in Phase 1 for oncology. The company is backed by venture capital, led by an experienced team, and its foundational technology has a proven track record, having contributed to the discovery of the marketed RSV antibody nirsevimab (Beyfortus™).

Proprietary B cell immortalization technology enabling two platforms: 1) Kling-Select for unbiased, simultaneous discovery of novel targets and fully human antibodies from patient-derived B cell libraries; 2) Kling-Evolve for ex vivo affinity maturation and directed evolution of antibody clones.

Kling operates in the highly competitive fields of antibody discovery and oncology therapeutics. It competes with large pharma and biotechs using various display technologies and single-cell genomics. Its key differentiation is the unbiased, patient-centric approach that discovers targets and antibodies simultaneously, a niche with few direct competitors.